- Home
- CVKD
as 07-26-2024 4:00pm EST
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 8.2M | IPO Year: | 2023 |
| Target Price: | $3.50 | AVG Volume (30 days): | 73.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $2.17 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cadrenal Therapeutics Inc. News
CVKD Breaking Stock News: Dive into CVKD Ticker-Specific Updates for Smart Investing
PR Newswire
9 days ago
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
GlobeNewswire
10 days ago
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
GlobeNewswire
a month ago
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
PR Newswire
a month ago
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
GlobeNewswire
2 months ago
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
PR Newswire
2 months ago
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
PR Newswire
2 months ago
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
PR Newswire
3 months ago
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
Compare CVKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CVKD Cadrenal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.